Treatment for autoimmune pancreatitis: consensus on the treatment for patients with autoimmune pancreatitis in Japan

被引:98
作者
Ito, Tetsuhide
Nishimori, Isao
Inoue, Naoko
Kawabe, Ken
Gibo, Junya
Arita, Yoshiyuki
Okazaki, Kazuichi
Takayanagi, Ryoichi
Otsuki, Makoto
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Higashi Ku, Fukuoka 8128582, Japan
[2] Kochi Med Sch, Dept Gastroenterol & Hepatol, Kochi, Japan
[3] Kansai Med Univ, Dept Internal Med 3, Kansai, Japan
关键词
autoimmune pancreatitis; steroid; therapy; survey;
D O I
10.1007/s00535-007-2051-y
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Autoimmune pancreatitis (AIP) has been characterized by unique clinical imaging, immunological findings, and the effectiveness of steroid therapy. A set of clinicopathological criteria for AIP was proposed by the Japan Pancreatic Society in 2002, and AIP has come to be widely recognized among general digestive clinicians. However, the indication of steroid therapy for AIP is still not well established, and furthermore the therapeutic doses and method of administration of steroid therapy is also unclear. Recently, an epidemiological survey of all the treatments used for AIP in Japan was conducted by the Research Committee of Intractable Pancreatic Diseases, and their report "Consensus for a Treatment of Autoimmune Pancreatitis" was produced. In a comparison of the results of steroid therapy and nonsteroid therapy for AIP in relation to the rate of complete remission, the recurrence rate, and the period needed to guarantee complete remission, it was thought that the administration of a steroid should be a standard therapy for AIR However, if the diagnosis of AIP is still uncertain, steroid therapy should be given with caution. In addition, even when AIP still appears to be possible after a course of steroid therapy, a re-evaluation should be carried out taking pancreatic carcinoma into consideration. An initial steroid dose of 30-40mg per day is recommended. With continuous and careful observations of the clinical manifestations, laboratory data, and imaging findings after administration of the initial dose of steroid for 2-4 weeks, the quantity of steroid can be reduced gradually to a maintenance dose in 2-3 months, and then reduced to 2.5-5 mg per day after remission. The recommended period of maintenance treatment is still unclear, but the administration of the steroid could be stopped after a period of about 6-12 months of treatment, although the patient should be monitored for clinical manifestations of improvement. In addition, the patient's progress should be followed taking recurrence into consideration. In order to evaluate the effectiveness of steroid therapy, follow-up observations should include biochemical examinations of blood findings such as serum gamma-globulin, IgG, and IgG 4, imaging findings, and clinical manifestations such as jaundice and abdominal discomfort.
引用
收藏
页码:50 / 58
页数:9
相关论文
共 27 条
[1]
High serum IgG4 concentrations in patients with sclerosing pancreatitis. [J].
Hamano, H ;
Kawa, S ;
Horiuchi, A ;
Unno, H ;
Furuya, N ;
Akamatsu, T ;
Fukushima, M ;
Nikaido, T ;
Nakayama, K ;
Usuda, N ;
Kiyosawa, K .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :732-738
[2]
Involvement of the Biliary System in Autoimmune Pancreatitis: A Follow-up Study [J].
Hirano, Kenji ;
Shiratori, Yasushi ;
Komatsu, Yutaka ;
Yamamoto, Natsuyo ;
Sasahira, Naoki ;
Toda, Nobuo ;
Isayama, Hiroyuki ;
Tada, Minoru ;
Tsujino, Takeshi ;
Nakata, Ryo ;
Kawase, Tateo ;
Katamoto, Tetsuo ;
Kawabe, Takao ;
Omata, Masao .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2003, 1 (06) :453-464
[3]
Autoimmune pancreatitis as a new clinical entity - Three cases of autoimmune pancreatitis with effective steroid therapy [J].
Ito, T ;
Nakano, I ;
Koyanagi, S ;
Miyahara, T ;
Migita, Y ;
Ogoshi, K ;
Sakai, H ;
Matsunaga, S ;
Yasuda, O ;
Sumii, T ;
Nawata, H .
DIGESTIVE DISEASES AND SCIENCES, 1997, 42 (07) :1458-1468
[4]
A new clinicopathological entity of IgG4-related autoimmune disease [J].
Kamisawa, T ;
Funata, N ;
Hayashi, Y ;
Eishi, Y ;
Koike, M ;
Tsuruta, K ;
Okamoto, A ;
Egawa, N ;
Nakajima, H .
JOURNAL OF GASTROENTEROLOGY, 2003, 38 (10) :982-984
[5]
Pancreatic endocrine and exocrine function and salivary gland function in autoimmune pancreatitis before and after steroid therapy [J].
Kamisawa, T ;
Egawa, N ;
Inokuma, S ;
Tsuruta, K ;
Okamoto, A ;
Kamata, N ;
Nakamura, T ;
Matsukawa, M .
PANCREAS, 2003, 27 (03) :235-238
[6]
Treating patients with autoimmune pancreatitis: Results from a long-term follow-up study [J].
Kamisawa, T ;
Yoshiike, M ;
Egawa, N ;
Nakajima, H ;
Tsuruta, K ;
Okamoto, A .
PANCREATOLOGY, 2005, 5 (2-3) :234-238
[7]
Successful treatment of advanced-stage autoimmune pancreatitis-related sclerosing cholangitis [J].
Kawabe, Ken ;
Ito, Tetsuhide ;
Arita, Yoshiyuki ;
Nakamuta, Makoto ;
Nawata, Hajime ;
Takayanagi, Ryoichi .
PANCREAS, 2006, 33 (04) :434-437
[8]
Autoimmune pancreatitis:: Pathological, clinical, and immunological features [J].
Klöppel, G ;
Lüttges, J ;
Löhr, M ;
Zamboni, G ;
Longnecker, D .
PANCREAS, 2003, 27 (01) :14-19
[9]
Members of the Criteria Committee for Autoimmune Pancreatitis of the Japan Pancreas Society. Diagnostic criteria for autoimmune pancreatitis by the Japan Pancreas Society, 2002, J JPN PANCREAS SOC, V17, P585
[10]
Nakazawa T, 2005, PANCREAS, V30, P20